Preclinical studies of the novel vascular disrupting agent MN-029

Anticancer Research

Volumn 25, Issue 6 B, 2005, Pages 3899-3904

  Shi, Wenyin ^a   Siemann, Dietmar W ^a,b  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

Cisplatin; MN 029; Radiation; Vascular disrupting agent

Indexed keywords

ANGIOGENESIS INHIBITOR; CISPLATIN; MN 029; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER MODEL; CELL DEATH; CELL KILLING; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SARCOMA; SOLID TUMOR; TUMOR NECROSIS; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; BENZIMIDAZOLES; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MICE; MICE, INBRED C3H; NECROSIS; NEOVASCULARIZATION, PATHOLOGIC; SARCOMA, EXPERIMENTAL;

EID: 27944450310     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Blakey DC, Ashton SE, Westwood FR, Walker M and Ryan AJ: ZD6126: a novel small molecule vascular targeting agent. Int J Radiat Oncol Biol Phys 54: 1497-1502, 2002.
2. Blakey DC, Westwood FR, Walker M, Hughes GD, Davis PD, Ashton SE and Ryan AJ: Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 8: 1974-1983, 2002.
3. Chaplin DJ and Dougherty GJ: Tumour vasculature as a target for cancer therapy. Br J Cancer 80(Suppl. 1): 57-64, 1999.
4. Ching LM, Joseph WR and Baguley BC: Antitumour responses to flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid in immune deficient mice. Br J Cancer 66: 128-130, 1992.
5. Cooney MM, Radivoyevitch T, Dowlati A, Overmoyer B, Levitan N, Robertson K, Levine SL, DeCaro K, Buchter C, Taylor A, Stambler BS and Remick SC: Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer. Clin Cancer Res 10: 96-100, 2004.
6. Curtis AS: Area and volume measurements by random sampling methods. Med Biol Illus 10: 261-266, 1960.
7. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR and Chaplin DJ: Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 57: 1829-1834, 1997.
8. Davis PD, Dougherty GJ, Blakey DC, Galbraith SM, Tozer GM, Holder AL, Naylor MA, Nolan J, Stratford MR, Chaplin DJ and Hill SA: ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res 62: 7247-7253, 2002.
9. Denekamp J: Vascular endothelium as the vulnerable element in tumours. Acta Radiol Oncol 23: 217-225, 1984.
10. Denekamp J: Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev 9: 267-282, 1990.
11. Denekamp J: Review article: angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol 66: 181-196, 1993.
12. Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, Rafie N, Overmoyer B, Makkar V, Stambler B, Taylor A, Waas J, Lewin JS, McCrae KR and Remick SC: A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 62: 3408-3416, 2002.
13. Folkman J: Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 333: 1757-1763, 1995.
14. Grosios K, Holwell SE, McGown AT, Pettit GR and Bibby MC: In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer 81: 1318-1327, 1999.
15. Hill SA, Toze GM, Pettit GR and Chaplin DJ: Preclinical evaluation of the antitumour activity of the novel vascular targeting agent Oxi 4503. Anticancer Res 22: 1453-1458, 2002.
16. Hori K, Saito S, Nihei Y, Suzuki M and Sato Y: Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC7700. Jpn J Cancer Res 90: 1026-1038, 1999.
17. Horsman MR, Ehrnrooth E, Ladekarl M and Overgaard J: The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors. Int J Radiat Oncol Biol Phys 42: 895-898, 1998.
18. Hua J, Sheng Y, Pinney KG, Garner CM, Kane RR, Prezioso JA, Pettit GR, Chaplin DJ and Edvardsen K: Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate. Anticancer Res 23: 1433-1440, 2003.
19. Kim S, Min SY, Lee SK and Cho WJ: Comparative molecular field analysis study of stilbene derivatives active against A549 lung carcinoma. Chem Pharm Bull (Tokyo) 57: 516-521, 2003.
20. Laws AL, Matthew AM, Double JA and Bibby MC: Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 71: 1204-1209, 1995.
21. Li L, Rojiani A and Siemann DW: Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy. Int J Radiat Oncol Biol Phys 42: 899-903, 1998.
22. Li L, Rojiani AM and Siemann DW: Preclinical evaluations of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi's sarcoma. Acta Oncol 41: 91-97, 2002.
23. Murata R, Overgaard J and Horsman MR: Combretastatin A-4 disodium phosphate: a vascular targeting agent that improves the anti-tumor effects of hyperthermia, radiation, and mild thermoradiotherapy. Int J Radiat Oncol Biol Phys 57: 1018-1024, 2001.
24. Murata R, Siemann DW, Overgaard J and Horsman MR: Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors. Radiother Oncol 60: 155-161, 2001.
25. Rewcastle GW, Atwell GJ, Li ZA, Baguley BC and Denny WA: Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids. J Med Chem 34: 217-222, 1991.
26. Rojiani AM, Li L, Rise L and Siemann DW: Activity of the vascular targeting agent combretastatin A-4 disodium phosphate in a xenograft model of AIDS-associated Kaposi's sarcoma. Acta Oncol 41: 98-105, 2002.
27. Rustin GJ, Galbraith SM, Anderson H, Stratford M, Folkes LK, Sena L, Gumbrell L and Price PM: Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 27: 2815-2822, 2003.
28. Siemann DW, Bibby MC, Dark GG, Dicker AP, Eskens FA, Horsman MR, Marme D and LoRusso PM: Differentiation and definition of vascular-targeted therapies. Clin Cancer Res 77: 416-420, 2005.
29. Siemann DW, Chaplin DJ and Horsman MR: Vascular-targeting therapies for treatment of malignant disease. Cancer 700: 2491-2499, 2004.
30. Siemann DW, Johansen IM and Horsman MR: Radiobiological hypoxia in the KHT sarcoma: predictions using the Eppendorf histograph. Int J Radiat Oncol Biol Phys 40: 1171-1176, 1998.
31. Siemann DW and Rojiani AM: Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 54: 1512-1517, 2002.
32. Siemann DW and Rojiani AM: Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 53: 164-171, 2002.
33. Siemann DW and Shi W: Targeting the tumor blood vessel network to enhance the efficacy of radiation therapy. Semin Radiat Oncol 13: 53-61, 2003.
34. Smith KA, Hill SA, Begg AC and Denekamp J: Validation of the fluorescent dye Hoechst 33342 as a vascular space marker in tumours. Br J Cancer 57: 247-253, 1988.
35. Soltau J and Drevs J: ZD-6126 AstraZeneca. I Drugs 7: 380-387, 2004.
36. Thorpe PE: Vascular targeting agents as cancer therapeutics. Clin Cancer Res 10: 415-427, 2004.
37. Tozer GM, Prise VE, Wilson J, Locke RJ, Vojnovic B, Stratford MR, Dennis MF and Chaplin DJ: Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res 59: 1626-1634, 1999.
38. Vaupel P, Kallinowski P and Okunieff P: Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 46: 6449-6465, 1989.